bs-9759R-RBITC [Conjugated Primary Antibody]
CAP Polyclonal Antibody, RBITC Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: CAP

Immunogen Range: 65-160/1362


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 23476

Swiss Prot: O60885

Source: KLH conjugated synthetic peptide derived from human Brd4/CAP

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Brd4 belongs to the BET family, a group of structurally related proteins containing two bromodomains. Through these two domains, Brd4 associates with mitotic chromosomes and its expression correlates with cell growth. Expression of Brd4 inhibits cell cycle progression from G(1) to S, due to binding to the largest subunit of replication factor C (RFC) to prevent DNA elongation. Altered Brd4 function correlates with poorly differentiated carcinoma, with aggresive phenotype and a highly lethal outcome.

Conjugation: RBITC

Excitation/ Emission: 540nm/625nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IF(IHC-P)(1:50-200)

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Kun Hao. et al. Targeting BRD4 prevents acute gouty arthritis by regulating pyroptosis. Int J Biol Sci. 2020; 16(16): 3163C3173Read more>>
  • Zhijie Wang. et al. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases. J MED CHEM. 2023;XXXX(XXX):XXX-XXXRead more>>